In an opioid emergency... **SECONDS COUNT**

REACH FOR VOICE GUIDANCE

DISPENSE EVZIO 2 MG

EVZIO is the first and only 2 mg take-home naloxone auto-injection system for use in opioid emergencies, including those due to synthetic opioids like fentanyl, long-acting opioids, and partial agonists or mixed agonist/antagonists. These may require higher or repeat doses of naloxone.1-3

**INTELLIGENT VOICE GUIDANCE:** Simple, on-the-spot voice and visual guidance helps caregivers take fast, confident action administering naloxone during an opioid emergency and reminds the user to call 9113-5

— Each prescription includes a Trainer for EVZIO, allowing patients and caregivers to practice3

**EASY TO USE:** Studies show 94% of users correctly administered EVZIO without training, and 100% with training4

**SELF-CONTAINED SYSTEM:** Prefilled, durable, and portable—small enough to fit in most pockets3,5

— Is administered intramuscularly or subcutaneously into the outer thigh, through clothing if needed3

*Based on the average results from 2 adequate and well-controlled usability studies.

**IF THERE ARE INSURANCE OR AFFORDABILITY QUESTIONS, YOU OR YOUR PATIENTS CAN CALL THE**

**EVZIO EZ HOTLINE**

**(877) 438-9463**

†Terms and Conditions apply. Maximum reimbursement limits apply. Only applies to patients with commercial insurance; patients covered by government programs are not eligible.

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

Please see additional Important Safety Information on back. Please see full Prescribing Information affixed on back and at EVZIO.com.

<table>
<thead>
<tr>
<th>Drug Description</th>
<th>Package Description</th>
<th>Dosage Form and Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVZIO® (naloxone HCl injection) 2 mg auto-injector</td>
<td>Carton containing 2 EVZIO auto-injectors and 1 Trainer</td>
<td>Injection: 2 mg/0.4 mL naloxone HCl solution in a prefilled auto-injector. Each EVZIO delivers 2 mg naloxone HCl injection (0.4 mL)</td>
</tr>
</tbody>
</table>

NDC 60842-051-01

Storage and Handling

Store at controlled room temperature 15°C to 25°C (59°F to 77°F); excursions permitted between 4°C and 40°C (39°F to 104°F)
IMPORTANT SAFETY INFORMATION (continued)

Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

The following warnings and precautions should be taken when administering EVZIO:

- **Risk of Recurrent Respiratory and CNS Depression**: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeated doses of naloxone using a new EVZIO, as necessary, while awaiting emergency medical assistance.

- **Risk of Limited Efficacy With Partial Agonists or Mixed Agonists/Antagonists**: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

- **Precipitation of Severe Opioid Withdrawal**: Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.

- **Risk of Cardiovascular (CV) Effects**: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information affixed below and at EVZIO.com.


©2017 kaleo, Inc. All rights reserved. PP-EVZ-US-1245. February 2017.